A. D. Pover

发表

Endogenous digitalis-like factor and inotropic receptor sites in rat heart.

A. D. Pover, 1984 .

Abstract 3748: NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent

C. Schnell, F. Hofmann, S. Brachmann, 2012 .

C. Darimont, N. Gradoux, A. D. Pover, 1999 .

Influence of 16β formylation on Na, K-ATPase inhibition by cardiac glycosides

T. Godfraind, A. D. Pover, 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Kinetic Study of Human Full-Length Wild-Type JAK2 and V617F Mutant Proteins

D. Erdmann, F. Hofmann, P. Chène, 2009 .

Study of the Selectivity of Insulin-Like Growth Factor-1 Receptor (IGF1R) Inhibitors

D. Erdmann, P. Chène, J. Bohn, 2014 .

Dihydroouabain is an antagonist of ouabain inotropic action

T. Godfraind, A. D. Pover, J. Ghysel‐Burton, 1982, Nature.